NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?
Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals.
See our latest analysis for Regeneron Pharmaceuticals.
At a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following...